SLN Silence Therapeutics Plc ADRs

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom. This is an ADR of a company whose stock trades outside of the U.S. as the symbol LN:SLN.

$21.08  -1.89 (-8.23%)
As of 10/19/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  09/08/2020
Outstanding shares:  29,911,816
Average volume:  1,722
Market cap:   $687,074,414
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        GB00B9GTXM62
Sedol:      B9GTXM6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   27.36
PS ratio:   436.71
Return on equity:   -23.30%
Net income %:   -481.20%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy